MCRB earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.02. Updated 2026-07-23.
Seres Therapeutics (MCRB) Research Hub
Seres Therapeutics (MCRB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.01 USD (-5.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.02, market cap 0.05B. This hub links to the full technical, earnings and options research available for MCRB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.01 USD (-5.11%) |
| 52-week range | 4.38 USD – 8.25 USD |
| Trend regime | Range |
| 14-day RSI | 52.3 (Neutral) |
| Trailing P/E | -1.02 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
Available research for MCRB
Covered Call on MCRB: how it works, illustrative setup around the real 5.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MCRB: how it works, illustrative setup around the real 5.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MCRB: how it works, illustrative setup around the real 5.01 USD price, max profit/loss, breakeven and when to use it. Educational.
MCRB technical analysis: range, last 5.01 USD, RSI 52.3, 52w range 4.38 USD–8.25 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MCRB in?
Seres Therapeutics (MCRB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MCRB in an uptrend or downtrend?
As of 2026-09-11, MCRB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MCRB's trailing P/E ratio?
MCRB's trailing P/E is -1.02, with a market cap of 0.05B. See the earnings research page for full valuation detail.